Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anterior Cruciate Ligament Reconstruction | 1 | 2014 | 1 | 0.450 |
Why?
|
| Muscle Strength | 1 | 2014 | 9 | 0.440 |
Why?
|
| Testosterone | 1 | 2014 | 50 | 0.430 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 75 | 0.420 |
Why?
|
| Immunoconjugates | 2 | 2016 | 2 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2018 | 78 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 31 | 0.130 |
Why?
|
| Depression | 1 | 2018 | 128 | 0.130 |
Why?
|
| Bronchitis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Tracheitis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 3 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 9 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2016 | 16 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2007 | 23 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 73 | 0.120 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2014 | 2 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 6 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2014 | 11 | 0.110 |
Why?
|
| Perioperative Period | 1 | 2014 | 4 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2014 | 101 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 279 | 0.110 |
Why?
|
| Necrosis | 1 | 2013 | 30 | 0.100 |
Why?
|
| Male | 4 | 2018 | 3671 | 0.100 |
Why?
|
| Humans | 5 | 2018 | 6794 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 72 | 0.100 |
Why?
|
| Young Adult | 1 | 2014 | 567 | 0.090 |
Why?
|
| Neoplasms | 1 | 2013 | 92 | 0.090 |
Why?
|
| Adolescent | 1 | 2014 | 869 | 0.090 |
Why?
|
| Lactams, Macrocyclic | 2 | 2007 | 2 | 0.080 |
Why?
|
| Benzoquinones | 2 | 2007 | 4 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2007 | 26 | 0.080 |
Why?
|
| Adult | 1 | 2014 | 2113 | 0.070 |
Why?
|
| Middle Aged | 1 | 2014 | 2108 | 0.070 |
Why?
|
| Apoptosomes | 1 | 2007 | 1 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Animals | 4 | 2016 | 1875 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2016 | 27 | 0.060 |
Why?
|
| Quinones | 1 | 2004 | 1 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2004 | 6 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 10 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 19 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 53 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 39 | 0.050 |
Why?
|
| Female | 3 | 2018 | 4060 | 0.050 |
Why?
|
| Mice | 3 | 2013 | 746 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 14 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 27 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 147 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 321 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2016 | 2 | 0.030 |
Why?
|
| Ventilators, Mechanical | 1 | 2016 | 2 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2016 | 4 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2016 | 14 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 9 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cross Infection | 1 | 2016 | 12 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2016 | 19 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 46 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 48 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 19 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 11 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 124 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 95 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 80 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 156 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 258 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2013 | 3 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 2 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 9 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 38 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 231 | 0.020 |
Why?
|
| Shock, Hemorrhagic | 1 | 2007 | 1 | 0.020 |
Why?
|
| Jejunum | 1 | 2007 | 3 | 0.020 |
Why?
|
| Cytosol | 1 | 2007 | 26 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 27 | 0.020 |
Why?
|
| Hypoxia | 1 | 2007 | 37 | 0.020 |
Why?
|
| Calcium | 1 | 2007 | 117 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2007 | 246 | 0.010 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2004 | 2 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 2 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 8 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 6 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 73 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 53 | 0.010 |
Why?
|